The stock price of 2seventy bio Inc (NASDAQ: TSVT) has jumped by 0.20 compared to previous close of 4.97. Despite this, the company has seen a gain of 0.40% in its stock price over the last five trading days. businesswire.com reported 2025-04-16 that NEW YORK & NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 2seventy bio, Inc. (NasdaqGS: TSVT) to Bristol Myers Squibb (NYSE: BMY). Under the terms of the proposed transaction, shareholders of 2seventy will receive $5.00 in cash for each share of 2seventy that they own. KSF is seeking to determine whether this consideration and the process that led to it ar.
Is It Worth Investing in 2seventy bio Inc (NASDAQ: TSVT) Right Now?
Moreover, the 36-month beta value for TSVT is 1.00. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TSVT is 47.46M and currently, short sellers hold a 5.80% of that float. On April 18, 2025, TSVT’s average trading volume was 1.24M shares.
TSVT’s Market Performance
TSVT stock saw an increase of 0.40% in the past week, with a monthly gain of 0.40% and a quarterly increase of 104.10%. The volatility ratio for the week is 0.44%, and the volatility levels for the last 30 days are 0.49% for 2seventy bio Inc (TSVT).. The simple moving average for the past 20 days is 0.53% for TSVT’s stock, with a 24.17% simple moving average for the past 200 days.
Analysts’ Opinion of TSVT
Many brokerage firms have already submitted their reports for TSVT stocks, with Goldman repeating the rating for TSVT by listing it as a “Sell.” The predicted price for TSVT in the upcoming period, according to Goldman is $2 based on the research report published on June 06, 2024 of the previous year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see TSVT reach a price target of $18, previously predicting the price at $5. The rating they have provided for TSVT stocks is “Outperform” according to the report published on January 31st, 2024.
TSVT Trading at 27.53% from the 50-Day Moving Average
After a stumble in the market that brought TSVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.04% of loss for the given period.
Volatility was left at 0.49%, however, over the last 30 days, the volatility rate increased by 0.44%, as shares surge +0.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +81.75% upper at present.
During the last 5 trading sessions, TSVT rose by +0.40%, which changed the moving average for the period of 200-days by +22.96% in comparison to the 20-day moving average, which settled at $4.95. In addition, 2seventy bio Inc saw 69.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TSVT starting from Snow Jessica, who sale 2,298 shares at the price of $4.95 back on Mar 17 ’25. After this action, Snow Jessica now owns 254,193 shares of 2seventy bio Inc, valued at $11,364 using the latest closing price.
Baird William D III, the President and CEO of 2seventy bio Inc, sale 5,092 shares at $4.95 during a trade that took place back on Mar 17 ’25, which means that Baird William D III is holding 1,121,034 shares at $25,180 based on the most recent closing price.
Stock Fundamentals for TSVT
Current profitability levels for the company are sitting at:
- -2.81 for the present operating margin
- 0.35 for the gross margin
The net margin for 2seventy bio Inc stands at -1.51. The total capital return value is set at -0.24. Equity return is now at value -24.56, with -10.96 for asset returns.
Based on 2seventy bio Inc (TSVT), the company’s capital structure generated 0.54 points at debt to capital in total, while cash flow to debt ratio is standing at -0.35.
Currently, EBITDA for the company is -98.45 million with net debt to EBITDA at -1.76. When we switch over and look at the enterprise to sales, we see a ratio of 11.44. The receivables turnover for the company is 4.87for trailing twelve months and the total asset turnover is 0.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.67.
Conclusion
To wrap up, the performance of 2seventy bio Inc (TSVT) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
